These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 21231963

  • 1. Rabbit antithymocyte induction and dosing in deceased donor renal transplant recipients over 60 yr of age.
    Patel SJ, Knight RJ, Suki WN, Abdellatif A, Duhart BT, Krauss AG, Mannan S, Nezakatgoo N, Osama Gaber A.
    Clin Transplant; 2011; 25(3):E250-6. PubMed ID: 21231963
    [Abstract] [Full Text] [Related]

  • 2. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
    Mai ML, Ahsan N, Wadei HM, Genco PV, Geiger XJ, Willingham DL, Taner CB, Hewitt WR, Grewal HP, Nguyen JH, Hughes CB, Gonwa TA.
    Transplantation; 2009 Jan 27; 87(2):227-32. PubMed ID: 19155977
    [Abstract] [Full Text] [Related]

  • 3. Risk factors and consequences of delayed graft function in deceased donor renal transplant patients receiving antithymocyte globulin induction.
    Patel SJ, Duhart BT, Krauss AG, Moore LW, Egidi MF, Amiri HS, Gaber LW, Gaber AO.
    Transplantation; 2008 Jul 27; 86(2):313-20. PubMed ID: 18645496
    [Abstract] [Full Text] [Related]

  • 4. Reduced dose rabbit anti-thymocyte globulin induction for prevention of acute rejection in high-risk kidney transplant recipients.
    Klem P, Cooper JE, Weiss AS, Gralla J, Owen P, Chan L, Wiseman AC.
    Transplantation; 2009 Oct 15; 88(7):891-6. PubMed ID: 19935460
    [Abstract] [Full Text] [Related]

  • 5. Rabbit antithymocyte globulin as induction immunotherapy for pediatric deceased donor kidney transplantation.
    Kamel MH, Mohan P, Little DM, Awan A, Hickey DP.
    J Urol; 2005 Aug 15; 174(2):703-7. PubMed ID: 16006954
    [Abstract] [Full Text] [Related]

  • 6. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
    Farney AC, Doares W, Rogers J, Singh R, Hartmann E, Hart L, Ashcraft E, Reeves-Daniels A, Gautreaux M, Iskandar SS, Moore P, Adams PL, Stratta RJ.
    Transplantation; 2009 Sep 27; 88(6):810-9. PubMed ID: 19920781
    [Abstract] [Full Text] [Related]

  • 7. Low-dose thymoglobulin use in elderly renal transplant recipients is safe and effective induction therapy.
    Laftavi MR, Patel S, Soliman MR, Alnimri M, Kohli R, Said M, Pankewycz O.
    Transplant Proc; 2011 Mar 27; 43(2):466-8. PubMed ID: 21440735
    [Abstract] [Full Text] [Related]

  • 8. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A, Nart A, Taşli FA, Postaci H, Aykas A, Doğan M, Sahin T.
    Nephrology (Carlton); 2008 Feb 27; 13(1):80-6. PubMed ID: 18199109
    [Abstract] [Full Text] [Related]

  • 9. Impact of small variations in the delivered dose of rabbit antithymocyte induction therapy in kidney transplantation with early corticosteroid withdrawal.
    Tsapepas DS, Mohan S, Tanriover B, Dube G, Crew RJ, Cohen DJ, Hardy MA, Sandoval PR, Ratner LE.
    Transplantation; 2012 Aug 27; 94(4):325-30. PubMed ID: 22814328
    [Abstract] [Full Text] [Related]

  • 10. Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report.
    Stevens RB, Mercer DF, Grant WJ, Freifeld AG, Lane JT, Groggel GC, Rigley TH, Nielsen KJ, Henning ME, Skorupa JY, Skorupa AJ, Christensen KA, Sandoz JP, Kellogg AM, Langnas AN, Wrenshall LE.
    Transplantation; 2008 May 27; 85(10):1391-9. PubMed ID: 18497677
    [Abstract] [Full Text] [Related]

  • 11. Annual trends and triple therapy--1991-2000.
    Nishikawa K, Terasaki PI.
    Clin Transpl; 2001 May 27; ():247-69. PubMed ID: 12211788
    [Abstract] [Full Text] [Related]

  • 12. Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal.
    Saull HE, Enderby CY, Gonwa TA, Wadei HM.
    Clin Transplant; 2015 Jul 27; 29(7):573-80. PubMed ID: 25711849
    [Abstract] [Full Text] [Related]

  • 13. Induction therapy by anti-thymocyte globulin (rabbit) versus basiliximab in deceased donor renal transplants and the effect on delayed graft function and outcomes.
    Foster CE, Weng RR, Piper M, Laugenou K, Ichii H, Lakey J, Malinoski D.
    Transplant Proc; 2012 Jan 27; 44(1):164-6. PubMed ID: 22310605
    [Abstract] [Full Text] [Related]

  • 14. Low-dose rabbit antithymocyte globulin versus basiliximab induction therapy in low-risk renal transplant recipients: 8-year follow-up.
    Laftavi MR, Alnimri M, Weber-Shrikant E, Kohli R, Said M, Patel S, Pankewycz O.
    Transplant Proc; 2011 Mar 27; 43(2):458-61. PubMed ID: 21440733
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of extended-duration inpatient-to-outpatient rabbit antithymocyte globulin induction in de novo kidney transplant recipients: 6-month outcomes.
    Trofe-Clark J, Reese PP, Patel HJ, Jakobowski D, Goral S, Doll SL, Abt PL, Bloom RD.
    Transplantation; 2012 Sep 15; 94(5):506-12. PubMed ID: 22895613
    [Abstract] [Full Text] [Related]

  • 16. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM, Yang SL, Wu WZ, Tan JM.
    Chin Med J (Engl); 2011 Mar 15; 124(5):664-8. PubMed ID: 21518554
    [Abstract] [Full Text] [Related]

  • 17. Evaluating safety and efficacy of rabbit antithymocyte globulin induction in elderly kidney transplant recipients.
    Khanmoradi K, Knorr JP, Feyssa EL, Parsikia A, Jawa P, Dinh DB, Campos S, Zaki RF, Ortiz JA.
    Exp Clin Transplant; 2013 Jun 15; 11(3):222-8. PubMed ID: 23432665
    [Abstract] [Full Text] [Related]

  • 18. Experience with deceased donor kidney transplantation in 114 patients over age 60.
    Moore PS, Farney AC, Hartmann EL, Rogers J, Doares W, Gautreaux MD, Iskandar SS, Hairston G, Adams PL, Stratta RJ.
    Surgery; 2007 Oct 15; 142(4):514-23; discussion 523.e1-2. PubMed ID: 17950343
    [Abstract] [Full Text] [Related]

  • 19. Rabbit antithymocyte globulin is more beneficial in standard kidney than in extended donor recipients.
    Hardinger KL, Brennan DC, Schnitzler MA.
    Transplantation; 2009 May 15; 87(9):1372-6. PubMed ID: 19424038
    [Abstract] [Full Text] [Related]

  • 20. Antithymocyte globulin induction in living donor renal transplant recipients: final report of the TAILOR registry.
    Gaber AO, Matas AJ, Henry ML, Brennan DC, Stevens RB, Kapur S, Ilsley JN, Kistler KD, Cosimi AB, Thymoglobulin Antibody Immunosuppression in Living Donor Recipients Investigators.
    Transplantation; 2012 Aug 27; 94(4):331-7. PubMed ID: 22850297
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.